Brooklyn Bodegas Sell $95 Retatrutide Over the Counter as Fake Lab Reports Surface
Updated
Updated · CBS New York · Jul 2
Brooklyn Bodegas Sell $95 Retatrutide Over the Counter as Fake Lab Reports Surface
3 articles · Updated · CBS New York · Jul 2
Summary
$95 bought a vial advertised as retatrutide at a Brooklyn bodega with no prescription, age check or medical screening, showing the experimental obesity drug has moved from online sellers into neighborhood stores.
Federal law bars commercial sales of unapproved drugs to the public, yet storefront posters at multiple New York bodegas promoted retatrutide for weight management even while labeling the peptides as not for human consumption.
Indr Labs, named on the vial, claimed third-party testing and at least 98% purity, but a supposed certificate appeared to identify tirzepatide instead, and Vanguard Laboratory said the reports attributed to it were fake.
FDA has warned that research-use retatrutide products are of unknown quality and may be harmful, while Eli Lilly urged regulators and law enforcement to dismantle black-market networks selling the drug.
Retatrutide's strong trial results have fueled demand before any FDA approval, even as poison centers report rising toxicity cases and the FDA receives more adverse-event complaints.
A drug promising surgery-like results is now sold in corner stores. Has the FDA lost control of the weight-loss black market?
Its lab reports are proven fakes. So what's actually inside the bootleg weight-loss vials sold openly in New York?
Brooklyn Bodegas Selling Experimental Weight-Loss Drugs: A Deep Dive into the Unregulated Retatrutide Market
Overview
A CBS News investigation uncovered that retatrutide, an experimental weight-loss drug not approved by the FDA, is being sold in Brooklyn convenience stores. This alarming trend shows how unapproved drugs are moving from loosely regulated online markets into everyday retail locations. The widespread sale of retatrutide, despite federal prohibition, highlights a serious issue called 'regulatory lag,' where excitement from clinical research outpaces official approval and safety checks. As a result, consumers are exposed to significant health risks, with dangerous substances becoming easily accessible before proper oversight is in place.